Trigriluzole(Trigriluzole) - 药物靶点：EAAT2 x NMDA receptor x Nav1.5 x VGSCs_在研适应症：马查多-约瑟夫病，强迫症，脊髓小脑性共济失调_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Trigriluzole-Biohaven Pharmaceuticals、Troriluzole、Troriluzole-hydrochloride

+ [6]

靶点

EAAT2 x NMDA receptor x Nav1.5 x VGSCs

作用机制

EAAT2调节剂(solute carrier family 1 member 2 modulators)、NMDA receptor拮抗剂(谷氨酸[NMDA]受体复合体拮抗剂)、Nav1.5阻滞剂(V型钠通道蛋白α亚基阻滞剂)

治疗领域

神经系统疾病遗传病与畸形其他疾病+ [3]

在研适应症

马查多-约瑟夫病强迫症脊髓小脑性共济失调+ [6]

非在研适应症

阿尔茨海默症焦虑症广泛性焦虑障碍+ [2]

原研机构

Yale University

在研机构

Biohaven Pharmaceuticals, Inc.朴莱雷斯集团

Bayer AG

+ [7]

非在研机构-

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评优先审评 (美国)、快速通道 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C15H17ClF3N5O4S

InChIKeyZRZLEMQBDKNTLJ-UHFFFAOYSA-N

CAS号1926204-76-3

关联

18

项与 Trigriluzole 相关的临床试验

NCT06552260

/ Not yet recruiting早期临床1期IIT

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

This research study is studying troriluzole as a possible treatment for recurrent glioblastoma.
The name of the study drug involved in this research study is:
-Troriluzole (a tripeptide prodrug of riluzole)

开始日期2025-02-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+2]

CTR20220688

/ Recruiting临床3期

一项Troriluzole ？助治疗强迫症受试者的多中心、48周、开放标签安全性研究

本研究的主要目的是在根据主方案（？BHV4157-302 和BHV4157-303 研究）定义的对OCD标准治疗（SOC）反应不佳的OCD受试者中，评价troriluzole作为辅助治疗的长期安全性和耐受性。

开始日期2023-01-31

申办/合作机构

标新有限公司

[+1]

CTR20212534

/ Recruiting临床3期

一项Troriluzole用于辅助治疗强迫症的随机、双盲、安慰剂对照试验

本研究的主要目的是与安慰剂相比，基于Y-BOCS评分的变化，评价Troriluzole作为辅助治疗用于对当前OCD治疗效果不佳的OCD受试者的疗效。

开始日期2022-07-19

申办/合作机构

标新有限公司

[+1]

100 项与 Trigriluzole 相关的临床结果

登录后查看更多信息

100 项与 Trigriluzole 相关的转化医学

登录后查看更多信息

100 项与 Trigriluzole 相关的专利（医药）

登录后查看更多信息

17

项与 Trigriluzole 相关的文献（医药）

2025-01-01·JOURNAL OF NEUROCHEMISTRY

Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg‐AD mice

Article

作者: Perman, Savannah ; Coric, Vladimir ; Pfitzer, Jeremiah ; Reed, Miranda N. ; Suppiramaniam, Vishnu ; Pinky, Priyanka D. ; Redmon, Emma ; Gramlich, Michael W. ; Qureshi, Irfan A. ; Cmelak, Luca

Abstract:

Alzheimer's disease (AD) is a neurodegenerative condition in which clinical symptoms are highly correlated with the loss of glutamatergic synapses. While later stages of AD are associated with markedly decreased glutamate levels due to neuronal loss, in the early stages, pathological accumulation of glutamate and hyperactivity contribute to AD pathology and cognitive dysfunction. There is increasing awareness that presynaptic dysfunction, particularly synaptic vesicle (SV) alterations, play a key role in mediating this early‐stage hyperactivity. In the current study, we sought to determine whether the 3xTg mouse model of AD that exhibits both beta‐amyloid (Aβ) and tau‐related pathology would exhibit similar presynaptic changes as previously observed in amyloid or tau models separately. Hippocampal cultures from 3xTg mice were used to determine whether presynaptic vesicular glutamate transporters (VGlut) and glutamate are increased at the synaptic level while controlling for postsynaptic activity. We observed that 3xTg hippocampal cultures exhibited increased VGlut1 associated with an increase in glutamate release, similar to prior observations in cultures from tau mouse models. However, the SV pool size was also increased in 3xTg cultures, an effect not previously observed in tau mouse models but observed in Aβ models, suggesting the changes in pool size may be due to Aβ and not tau. Second, we sought to determine whether treatment with troriluzole, a novel 3rd generation tripeptide prodrug of the glutamate modulator riluzole, could reduce VGlut1 and glutamate release to restore cognitive deficits in 8‐month‐old 3xTg mice. Treatment with troriluzole reduced VGlut1 expression, decreased basal and evoked glutamate release, and restored cognitive deficits in 3xTg mice. Together, these findings suggest presynaptic alterations are early events in AD that represent potential targets for therapeutic intervention, and these results support the promise of glutamate‐modulating drugs such as troriluzole in Alzheimer's disease. image

2024-08-01·Neurology and Therapy

Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis

Article

作者: Perlman, Susan ; Maclaine, Grant D H ; L'Italien, Gilbert J ; Coric, Vladimir ; Khera, Rohan ; Potashman, Michele H ; Schmahmann, Jeremy D ; Beiner, Melissa W ; Oikonomou, Evangelos K

INTRODUCTION:

Traditional methods for assessing movement quality rely on subjective standardized scales and clinical expertise. This limitation creates challenges for assessing patients with spinocerebellar ataxia (SCA), in whom changes in mobility can be subtle and varied. We hypothesized that a machine learning analytic system might complement traditional clinician-rated measures of gait. Our objective was to use a video-based assessment of gait dispersion to compare the effects of troriluzole with placebo on gait quality in adults with SCA.

METHODS:

Participants with SCA underwent gait assessment in a phase 3, double-blind, placebo-controlled trial of troriluzole (NCT03701399). Videos were processed through a deep learning pose extraction algorithm, followed by the estimation of a novel gait stability measure, the Pose Dispersion Index, quantifying the frame-by-frame symmetry, balance, and stability during natural and tandem walk tasks. The effects of troriluzole treatment were assessed in mixed linear models, participant-level grouping, and treatment group-by-visit week interaction adjusted for age, sex, baseline modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA), and time since diagnosis.

RESULTS:

From 218 randomized participants, 67 and 56 participants had interpretable videos of a tandem and natural walk attempt, respectively. At Week 48, individuals assigned to troriluzole exhibited significant (p = 0.010) improvement in tandem walk Pose Dispersion Index versus placebo {adjusted interaction coefficient: 0.584 [95% confidence interval (CI) 0.137 to 1.031]}. A similar, nonsignificant trend was observed in the natural walk assessment [coefficient: 1.198 (95% CI - 1.067 to 3.462)]. Further, lower baseline Pose Dispersion Index during the natural walk was significantly (p = 0.041) associated with a higher risk of subsequent falls [adjusted Poisson coefficient: - 0.356 [95% CI - 0.697 to - 0.014)].

CONCLUSION:

Using this novel approach, troriluzole-treated subjects demonstrated improvement in gait as compared to placebo for the tandem walk. Machine learning applied to video-captured gait parameters can complement clinician-reported motor assessment in adults with SCA. The Pose Dispersion Index may enhance assessment in future research. TRIAL REGISTRATION-CLINICALTRIALS.

GOV IDENTIFIER:

NCT03701399.

2024-03-01·JID innovations : skin science from molecules to population health

Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model

Article

作者: Reitz, Allen B ; Silk, Ann W ; Chaly, Anna ; Marinaro, Christina ; Chen, Suzie ; Putta, Sanjana ; Eddin, Mohamad Naser ; Furmanski, Philip ; Sauer, John Michael ; Pelletier, Jeffrey C ; Eddy, Kevinn ; Gupta, Kajal ; Zloza, Andrew ; Freeman, Katie B ; Fateeva, Anna

Previous work done by our laboratory described the use of an immunocompetent spontaneous melanoma-prone mouse model, TGS (TG-3/SKH-1), to evaluate treatment outcomes using inhibitors of glutamatergic signaling and immune checkpoint for 18 weeks. We showed a significant therapeutic efficacy with a notable sex-biased response in male mice. In this follow-up 18-week study, the dose of the glutamatergic signaling inhibitor was increased (from 1.7 mg/kg to 25 mg/kg), which resulted in improved responses in female mice but not male mice. The greatest reduction in tumor progression was observed in male mice treated with single-agent troriluzole and anti-PD-1. Furthermore, a randomly selected group of mice was removed from treatment after 18 weeks and maintained for up to an additional 48 weeks demonstrating the utility of the TGS mouse model to perform a ≥1-year preclinical therapeutic study in a physiologically relevant tumor-host environment. Digital spatial imaging analyses were performed in tumors and tumor microenvironments across treatment modalities using antibody panels for immune cell types and immune cell activation. The results suggest that immune cell populations and cytotoxic activities of T cells play critical roles in treatment responses in these mice. Examination of a group of molecular protein markers based on the proposed mechanisms of action of inhibitors of glutamatergic signaling and immune checkpoint showed that alterations in expression levels of xCT, γ-H2AX, EAAT2, PD-L1, and PD-1 are likely associated with the loss of treatment responses. These results suggest the importance of tracking changes in molecular markers associated with the mechanism of action of therapeutics over the course of a longitudinal preclinical therapeutic study in spatial and temporal manners.

68

项与 Trigriluzole 相关的新闻（医药）

2025-02-13

·SYNAPSE

2025年2月13日全球新药进展早知道

1. FDA批准SpringWorks别构小分子MEK抑制剂 2月12日，SpringWorks Therapeutics宣布，美国FDA已批准MEK抑制剂Gomekli（mirdametinib）上市，用于治疗肿瘤无法完全切除的年龄不低于2岁的1型神经纤维瘤病相关丛状神经纤维瘤（NF1-PN）成人和儿童患者。新闻稿指出，mirdametinib是首个获批可同时用于治疗成人和儿童NF1-PN的药物。Mirdametinib是一种口服别构小分子MEK抑制剂，靶向MEK1和MEK2。FDA的批准是基于2b期临床试验ReNeu的结果，该试验达到了ORR主要终点，成人患者的ORR为41%（24/58），儿童患者的ORR为52%（29/56）。在确认获得缓解的患者中，88%的成人和90%的儿童患者的缓解持续时间至少为12个月，而50%的成人患者和48%的儿童患者的缓解持续时间至少为24个月。 2. 欧盟批准BridgeBio创新疗法，已授权拜耳 2月12日，BridgeBio Pharma宣布，欧盟已经批准Beyonttra（acoramidis）用于治疗伴有心肌病的野生型或变异型转甲状腺素蛋白介导的淀粉样变性（ATTR-CM）成人患者。Acoramidis是一种口服的转甲状腺素蛋白小分子稳定剂，本次批准基于ATTRibute-CM关键研究的结果。该试验成功达成了其主要终点，在第30个月时，与安慰剂相比，acoramidis组的ACM和反复发生的CVH事件减少了42%。Acoramidis起效迅速，在接受治疗后仅3个月时，患者首次发生ACM或CVH事件所需时间就与安慰剂组产生差异。此前于2024年11月，美国FDA已经批准acoramidis上市（商品名：Attruby）用于治疗ATTR-CM患者。而该药在欧洲的独家商业化权利已于2024年3月授予拜耳（Bayer）公司，欧盟的批准将触发7500万美元的里程碑款项。 3. FDA受理再生元CD3/BCMA双抗上市申请 2月12日，再生元（Regeneron）宣布，美国FDA已受理其为CD3/BCMA双特异性抗体疗法linvoseltamab所重新提交的生物制品许可申请（BLA），用于治疗已接受至少四线治疗，或已接受三线治疗且对最后一线治疗耐药的成年复发/难治性多发性骨髓瘤（MM）患者。FDA预计在2025年7月10日前对该申请做出审评决定。Linvoseltamab同时正在接受欧洲药品管理局（EMA）针对相同患者群体的审评。此次BLA重新提交的受理是在再生元解决第三方充填/封装制造问题之后进行的，该问题是FDA在之前该公司BLA提交中所唯一提出的问题。该BLA得到了关键性LINKER-MM1试验数据的支持。 4. Biohaven创新疗法在美国申报上市，获优先审评资格 2月12日，Biohaven宣布，美国FDA已受理该公司在研疗法troriluzole用于治疗成人脊髓小脑共济失调症（SCA）的新药申请（NDA），并授予优先审评资格。根据一项真实世界证据（RWE）研究，经3年治疗后，troriluzole可将SCA患者的病情进展减缓最高达70%。根据新闻稿，若获批准，该药将成为首个获FDA批准用于治疗SCA的药物。这次NDA的递交主要基于BHV4157-206-RWE试验的积极结果。该试验是在与美国FDA讨论后设计的关键性临床研究，旨在评估troriluzole在SCA患者中的疗效，以治疗3年后功能性共济失调评分（f-SARA）变化为衡量指标。该研究利用了3期临床试验数据，并根据FDA的RWE指南，使用来自美国小脑性共济失调临床研究联盟（CRC-SCA）的未治疗SCA患者作为外部对照。多项分析的数据综合显示，在troriluzole治疗组中，SCA患者病情恶化的速度减慢了50%-70%，在3年的研究期间，疾病进展延缓了1.5至2.2年。 5. 诺和诺德「司美格鲁肽」新适应症在中国申报上市 2月12日，CDE官网最新公示，诺和诺德（Novo Nordisk）申报的3.1类新药司美格鲁肽注射液新适应症上市申请获得受理，尚无具体适应症信息披露。根据注册分类及诺和诺德公开资料推测，这可能是司美格鲁肽2.4mg注射剂（商品名为Wegovy），此前已经在中国获批用于长期体重管理。本次该产品在中国申报上市的适应症可能为用于低已确诊心血管疾病的肥胖或超重成人的主要不良心血管事件（MACE）风险。 6. 首个国产FXI抑制剂进入III期阶段，来自恒瑞医药 2月12日，药物临床试验登记与信息公示平台显示，恒瑞医药启动了新型抗凝药SHR-2004的首个III期临床试验。SHR-2004是一种靶向凝血因子XI（FXI）的人源化单克隆抗体，可选择性结合FXI和凝血因子XIa（FXIa），阻碍凝血因子XIIa（FXIIa）对FXI的激活，从而阻断内源性凝血途径的级联反应过程，发挥抗凝作用。目前，全球尚无FXI/FXIa抑制剂上市。本次启动的III期研究是一项多中心、随机、双盲、阳性药物对照临床试验（n=1167），旨在评估接受全膝关节置换术后的成人患者使用SHR-2004（皮下注射，120mg，用药1次或静脉输注1次，90mg，用药1次）或依诺肝素钠（皮下注射，40mg，用药12-14次）或安慰剂预防静脉血栓栓塞症（VTE）的有效性和安全性。 7. GenSight公司发布一次性基因治疗眼科临床结果 2月12日，GenSight Biologics发布了其LUMEVOQ®基因疗法治疗Leber遗传性视神经病变(LHON)的REFLECT III期临床试验五年疗效和安全性的最终结果。结果显示，单次注射LUMEVOQ®后五年，患者视力改善持续存在，且安全性良好。双侧注射相比单侧注射，具有额外获益，尤其在临床相关恢复率方面。LHON 是一种罕见的母系遗传线粒体遗传疾病，会导致视网膜神经节细胞变性，从而导致突然且不可逆转的视力丧失，并可能导致法定失明。LUMEVOQ 是一种针对LHON的基因疗法，通过玻璃体内注射的方式单次给药，旨在为患者提供可持续的功能性视力恢复。 1. 超21亿美元！艾伯维与Xilio合作开发实体瘤TCE 2月12日，艾伯维和 Xilio Therapeutics宣布达成合作和许可选择协议，利用 Xilio 的专有技术开发新型肿瘤激活、基于抗体的免疫疗法，包括掩蔽型T细胞衔接器。Xilio 盘前股票涨幅超170%。根据协议条款，Xilio 将获得总计5200 万美元的预付款，包括1000万美元的股权投资，并有资格获得高达约21亿美元的期权相关费用和里程碑付款以及分级特许权使用费总额。内容来源于网络，如有侵权，请联系删除。

上市批准临床结果临床申请合作

2025-02-11

·药明康德

潜在首款！病情恶化速度减缓达70%，创新小分子获优先审评资格

▎药明康德内容团队编辑 Biohaven今天宣布，美国FDA已受理该公司在研疗法troriluzole用于治疗成人脊髓小脑共济失调症（SCA）的新药申请（NDA），并授予优先审评资格。根据一项真实世界证据（RWE）研究，经3年治疗后，troriluzole可将SCA患者的病情进展减缓最高达70%。根据新闻稿，若获批准，该药将成为首个获FDA批准用于治疗SCA的药物。脊髓小脑性共济失调是一种显性遗传的神经退行性疾病，其特征为自主运动控制的逐步丧失以及小脑、脑干和脊髓的萎缩。患者承受显著的疾病负担，包括需要轮椅、步态障碍导致跌倒、由于语言障碍无法交流、吞咽困难和过早死亡。目前，SCA没有FDA批准的治疗方法，也没有治愈手段。这次NDA的递交主要基于BHV4157-206-RWE试验的积极结果。该试验是在与美国FDA讨论后设计的关键性临床研究，旨在评估troriluzole在SCA患者中的疗效，以治疗3年后功能性共济失调评分（f-SARA）变化为衡量指标。该研究利用了3期临床试验数据，并根据FDA的RWE指南，使用来自美国小脑性共济失调临床研究联盟（CRC-SCA）的未治疗SCA患者作为外部对照。多项分析的数据综合显示，在troriluzole治疗组中，SCA患者的疾病进展获得显著且具有临床意义的减缓。治疗带来的益处使得相较于未治疗的患者，病情恶化的速度减慢了50%-70%，在3年的研究期间，疾病进展延缓了1.5至2.2年。 ▲f-SARA变化表明，troriluzole减缓了SCA疾病进展（图片来源：参考资料[1]）此外，预定的分析还采用了来自欧洲SCA自然病程研究（EUROSCA）的独立外部对照组，用于支持全球监管申请。使用EUROSCA患者以及结合CRC-SCA和EUROSCA患者作为外部对照的综合分析结果也在所有时间点上与主要疗效分析一致，且具有统计学显著性。EUROSCA数据的加入增加了外部对照样本数量，并增强了在第1、第2和第3年troriluzole治疗差异的统计学显著性。 Troriluzole的主要作用机制是减少突触中的谷氨酸水平。Troriluzole增强了位于胶质细胞上的兴奋性氨基酸的转运体表达和功能，这些转运体在清除突触中的谷氨酸方面发挥着关键作用。Troriluzole有潜力在多种与谷氨酸过量相关的疾病中得到进一步开发。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia. Retrieved February 11, 2025 from https://www.prnewswire.com/news-releases/biohaven-announces-fda-acceptance-and-priority-review-of-troriluzole-new-drug-application-for-the-treatment-of-spinocerebellar-ataxia-302373056.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

优先审批申请上市临床3期

2025-02-11

·EndPoints

Biohaven lands priority review on second-chance application for neurodegenerative drug

Biohaven’s experimental drug troriluzole for the rare, neurodegenerative disease spinocerebellar ataxia will get a priority review from the FDA, after the company presented additional real-world data. The Connecticut-based biotech said Tuesday that an FDA decision could come in the third quarter of this year, and that it’s prepared to commercialize troriluzole this year. SCA is a a rare, genetic disease that affects about 15,000 Americans and can lead to premature death as well as mobility and speech impairment. If approved, troriluzole would be the first and only treatment for the disease. In July 2023, the FDA issued a refuse-to-file letter for Biohaven’s troriluzole application after a Phase 3 trial missed its primary endpoint. In the new application, the company included real-world evidence that it says shows that the drug can significantly slow disease progression compared with natural history populations. TD Cowen analysts said in a note that they are projecting $1.4 billion in peak annual sales (based on a net price of $30,000 per month) and expect an FDA decision in August. On the latest update, TD Cowen adds, “we interpret the FDA’s decision to grant Priority Review as validation of the agency’s recognition of both the rigor of the data package and troriluzole’s value proposition for SCA patients, and we are increasingly confident in the likelihood of approval.” William Blair analysts model an 85% probability of approval and peak sales of $626 million in the US, assuming a list price at launch of $37,000. It’s still an open question if the FDA will call an advisory committee to review troriluzole, but analysts say that if an adcomm is not called, the likelihood of approval goes even higher. Biohaven stock $BHVN was up more than 12% on Tuesday afternoon.

优先审批临床3期

100 项与 Trigriluzole 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Trigriluzole	-	DB15079

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
马查多-约瑟夫病	申请上市	美国	Biohaven Ltd.	2023-05-31
强迫症	临床3期	中国	Biohaven Pharmaceuticals, Inc.	2021-01-29
强迫症	临床3期	加拿大	Biohaven Pharmaceuticals, Inc.	2021-01-29
强迫症	临床3期	意大利	Biohaven Pharmaceuticals, Inc.	2021-01-29
强迫症	临床3期	荷兰	Biohaven Pharmaceuticals, Inc.	2021-01-29
强迫症	临床3期	西班牙	Biohaven Pharmaceuticals, Inc.	2021-01-29
强迫症	临床3期	英国	Biohaven Pharmaceuticals, Inc.	2021-01-29
脊髓小脑性共济失调	临床3期	中国	标新有限公司	2020-11-20
多形性胶质母细胞瘤	临床3期	美国	Bayer AG	2019-07-30
多形性胶质母细胞瘤	临床3期	美国	Vigeo Therapeutics, Inc.	2019-07-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06529146 (BHV4157-206-RWE, Company_Website) 人工标引	N/A	脊髓小脑性共济失调	-	Troriluzole	範築鑰製淵選築簾選顧(顧憲蓋築膚壓襯繭鬱顧) = troriluzole 200 mg dosed orally in patients with SCA met the study's primary endpoint of change from baseline. 鏇繭鹹繭襯範襯廠蓋夢 (醖鹽夢觸繭艱觸鏇膚鹽 ) 达到更多	积极	2025-02-11
				external control arm
NCT03701399 (Phase III Clinical Trial of Troriluzole, CTgov)	临床3期	脊髓小脑性共济失调10型 \| 马查多-约瑟夫病 \| 脊髓小脑性共济失调8型	299	troriluzole (Troriluzole)	積鏇簾壓艱積衊窪壓顧(憲積窪遞鹹壓選觸壓鏇) = 網膚憲鹹獵願獵膚鏇鹽衊蓋淵範鏇衊遞積鏇顧 (夢蓋淵製顧餘廠憲夢壓, 醖鬱艱糧衊襯願選蓋範 ~ 餘鹽簾膚範獵淵築醖鑰) 更多	-	2025-02-10
				Placebo+troriluzole (Placebo)	積鏇簾壓艱積衊窪壓顧(憲積窪遞鹹壓選觸壓鏇) = 繭選鏇製衊鹹鬱願積網衊蓋淵範鏇衊遞積鏇顧 (夢蓋淵製顧餘廠憲夢壓, 憲鑰選構夢鏇獵遞醖蓋 ~ 選憲選遞蓋餘鏇憲顧鬱) 更多
NEWS 人工标引	临床3期	脊髓小脑性共济失调	-	Troriluzole	壓範觸餘鹹艱築餘鏇壓(鹽鹹糧構築築鬱構艱襯) = Biohaven said that the once-daily oral drug met the primary endpoint across all genotypes of SCA included in the study and that it showed statistically significant superiority after both one and two years compared to the external control groups. 鹹願繭夢鏇鑰構積淵鏇 (範蓋餘繭鑰築鹽壓網膚 ) 达到更多	积极	2024-09-23
AAN2024	N/A	-	-	Troriluzole 200 mg	齋簾願鹹襯餘鏇鬱願餘(餘積糧選醖夢淵廠構鬱) = values were 40% and 50% higher after troriluzole 100 mg and 280 mg, respectively vs oral riluzole 50 mg 積獵鹽襯鹽夢衊膚鑰齋 (鹹膚構衊齋膚鏇範範襯 ) 更多	-	2024-04-09
				Troriluzole 280 mg
AAN2024	N/A	-	-	Troriluzole 140mg QD	膚齋夢糧積築糧艱齋鹽(繭餘衊艱蓋鬱餘廠襯廠) = 鬱齋衊積淵鹽壓廠淵積觸繭壓繭簾選窪鑰鑰膚 (繭襯壓製積鹹糧築網衊 ) 更多	-	2024-04-09
				Troriluzole 200mg QD	膚齋夢糧積築糧艱齋鹽(繭餘衊艱蓋鬱餘廠襯廠) = 鑰鑰襯積選鹹構製艱遞觸繭壓繭簾選窪鑰鑰膚 (繭襯壓製積鹹糧築網衊 ) 更多
NCT03701399 (Phase III Clinical Trial of Troriluzole, AAN2024)	临床3期	脊髓小脑性共济失调	218	Troriluzole	淵獵窪鑰艱鏇製衊憲觸(願襯廠窪築願遞淵鬱鑰): adj. interaction coefficient = 0.58 (95% CI, 0.14 ~ 1.03)	积极	2024-04-09
				Placebo
NCT04899921 (CTgov)	临床2期	转移性黑色素瘤	1	ipilimumab+Troriluzole+nivolumab (Ipilimumab + Nivolumab + Troriluzole [Phase I Dose Level 1])	襯構襯鹹網膚蓋襯遞壓(餘構範鬱積鹹壓蓋簾糧) = 淵衊鑰築觸顧襯廠壓顧鬱衊積選糧鹹遞蓋選遞 (觸鏇齋鏇襯獵鏇鹹糧鑰, 壓簾遞艱範網獵餘衊襯 ~ 鏇鑰憲夢衊餘餘觸積觸) 更多	-	2023-12-13
				ipilimumab+Troriluzole+nivolumab (Ipilimumab + Nivolumab + Troriluzole [Phase I Dose Level 2])	襯構襯鹹網膚蓋襯遞壓(餘構範鬱積鹹壓蓋簾糧) = 艱蓋積繭鹽遞構顧鑰鑰鬱衊積選糧鹹遞蓋選遞 (觸鏇齋鏇襯獵鏇鹹糧鑰, 襯繭齋鬱膚鬱糧觸觸衊 ~ 獵壓構襯膚夢鹹襯構淵) 更多
NCT03605667 (T2 Protect AD, CTgov)	临床2期	阿尔茨海默症	350	Placebo oral capsule	窪獵壓製衊糧範蓋壓憲(遞糧醖願繭選觸廠顧憲) = 糧衊製繭構製餘網夢廠鏇廠衊廠壓築餘網獵範 (鏇願範艱膚繭繭淵憲醖, 鹹築選遞醖積鬱襯繭選 ~ 築淵觸淵鏇鏇餘積蓋築) 更多	-	2023-12-06
NCT03299166 (CTgov)	临床2/3期	强迫症	426	Troriluzole (Troriluzole - Randomization Phase)	觸構衊糧蓋製積窪範願(範觸範衊艱醖糧鬱鬱廠) = 壓淵壓憲鑰願糧鏇衊餘選網淵窪簾壓觸餘網鏇 (繭糧衊獵製窪鬱糧築夢, 蓋願積糧構膚構廠鏇鹽 ~ 糧夢憲積廠選製製夢膚) 更多	-	2023-06-02
				placebo+troriluzole (Placebo - Randomization Phase)	觸構衊糧蓋製積窪範願(範觸範衊艱醖糧鬱鬱廠) = 夢鏇壓選積構鑰構憲鹽選網淵窪簾壓觸餘網鏇 (繭糧衊獵製窪鬱糧築夢, 積構積築淵夢觸選選積 ~ 齋鹹醖選艱鹹憲醖選觸) 更多
NCT03829241 (CTgov)	临床3期	广泛性焦虑障碍	881	Troriluzole (Troriluzole)	鏇積鹹鹹夢築衊餘範選(壓壓窪構糧網範鏇鹹餘) = 築醖齋衊鬱遞製觸獵獵願鏇鹽鹽壓齋窪築簾顧 (衊繭淵壓壓蓋餘壓鹹選, 壓膚鏇淵鹹窪憲選淵觸 ~ 窪觸遞鬱窪獵壓觸壓獵) 更多	-	2022-12-28
				Placebo+Troriluzole (Placebo)	鏇積鹹鹹夢築衊餘範選(壓壓窪構糧網範鏇鹹餘) = 觸鹽製蓋製網艱積蓋餘願鏇鹽鹽壓齋窪築簾顧 (衊繭淵壓壓蓋餘壓鹹選, 鑰糧鏇鏇構積蓋鹽構壓 ~ 廠襯鑰廠齋衊壓憲膚餘) 更多